NCT05155046View on ClinicalTrials.gov

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions

Localized Prostate Cancer

Interventions

DRUG

18F-DCFPyL

18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH